Universal reference book for medicines
Name of the drug: NAZOL ® KIDS (NAZOL KIDS)

Active substance: phenylephrine

Type: Vasoconstrictive drug for topical application in ENT practice

Manufacturer: BAYER (Russia) manufactured by ISTITUTO de ANGELI (Italy)
Composition, form of production and packaging
?
Spray nasal (for children) 0.25% in the form of a clear solution from colorless to light yellow color, with a faint odor of eucalyptus.
100 ml

phenylephrine hydrochloride 0.25 g

Excipients: benzalkonium chloride 0.018 g, eucalyptol (cineole) 0.04 g, glycerol 4 g, macrogol 1500 1.5 g, sodium hydrogen phosphate dihydrate 0.226 g, potassium dihydrogen phosphate 0.101 g, disodium edetate dihydrate 0.02 g, purified water - 95.845 g.

15 ml - polyethylene bottles (1) with a spraying device - packs cardboard.

30 ml - polyethylene bottles (1) with a spraying device - packs cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2013.

PHARMACHOLOGIC EFFECT

Vasoconstrictive drug for topical application in ENT-practice, agonist?
1- adrenoreceptors (sympathomimetic). Has vasoconstrictive effect due to stimulation? 1-adrenoreceptors in the nasal mucosa: reduces swelling, stagnation and flushing of tissues in the nasal mucosa, and improves the patency of the nasal airways.
PHARMACOKINETICS

With topical application of the drug, systemic absorption is low.

INDICATIONS

To facilitate breathing through the nose when:

- colds and flu;

- hay fever or other allergic diseases of the upper respiratory tract, accompanied by acute rhinitis or sinusitis.

DOSING MODE

Children aged 6 to 12 years are prescribed 2-3 injections in each nasal passage, not more often than every 4 hours.

SIDE EFFECT

From the side of the central nervous system: headache, dizziness, tremor, sleep disturbance.

From the cardiovascular system: palpitation, arrhythmia, increased blood pressure.

Local reactions: sometimes - burning, tingling or tingling in the nose.

Other: sweating, pallor.

CONTRAINDICATIONS

- diseases of the cardiovascular system (including pronounced atherosclerosis, angina pectoris, tachycardia);

- arterial hypertension;

- thyrotoxicosis;

- diabetes;

- Children's age up to 4 years;

- Hypersensitivity to the components of the drug.

PREGNANCY AND LACTATION

Sufficient experience in the use of the drug in pregnancy is not.

The use of the drug during pregnancy and lactation (breastfeeding) is possible only if the intended benefit to the mother exceeds the potential risk to the fetus or child.

APPLICATION FOR CHILDREN

Contraindicated in children under 4 years.
In children, the systemic absorption of phenylephrine and the associated risk of side effects are higher than in adults.
SPECIAL INSTRUCTIONS

In children, the systemic absorption of phenylephrine and the associated risk of side effects are higher than in adults.

The duration of the drug should not exceed 3 days, with the preservation of obstructed nasal breathing, further use of the drug should be agreed with the doctor.

Do not prescribe phenylephrine to patients within 2 weeks after the abolition of MAO inhibitors, as they can increase the severity of adrenergic effects of sympathomimetic drugs and increase the risk of cardiovascular side effects.

It is not recommended to use the same vial for several people, in order to avoid the spread of infection.

When the bottle is compressed in the vertical position, the solution is released from it in the form of a spray, when the bottle is compressed in an inverted position, dropwise.

OVERDOSE

Symptoms: violation of the heart rhythm, increased blood pressure, agitation.

Treatment: conduct symptomatic therapy.

DRUG INTERACTION

MAO inhibitors (procarbazine, selegiline), tricyclic antidepressants, maprotiline, guanedrel, guanethidine increase the pressor effect and arrhythmogenicity of phenylephrine (with systemic absorption).

Thyroid hormones increase (coupled with systemic absorption of phenylephrine) the associated risk of coronary insufficiency (especially in coronary atherosclerosis).

TERMS OF RELEASE FROM PHARMACY

The drug is approved for use as an OTC product for children from 6 years of age.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored in a dry, protected from light, out of reach of children at a temperature of 15 ° to 25 ° C.
Shelf life - 2 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!